Get started
REGENERON PHARMACEUTICALSREGENERON PHARMACEUTICALSREGENERON PHARMACEUTICALS

REGENERON PHARMACEUTICALS

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

4REGN trade ideas

REGN Stock - A Strong Buy OpportunityNASDAQ:REGN is in a historical bullish trend , and right now offers a potential buying opportunity: Discount at Strong Support : After a pullback, the stock has reached a key support level , providing a good entry point. Excellent Risk/Reward : With a 1:14 ratio to the all-time high (ATH) , the upside is significant for those willing to risk. Bullish Signals : Last week showed a strong bullish candle, and the rising volume over the past month suggests growing accumulation, indicating renewed buying momentum . Now could be an ideal time to buy, targeting a bounce back to the ATH.
NASDAQ:REGNLong
by PattRec
NASDAQ-REGN at a Crossroads: Breakdown or Breakout?The Market’s Dilemma: Is REGN Ready for a Reversal? The biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) is hovering at a critical juncture. Trading at $672.98, the stock has plummeted 44.4% from its all-time high of $1211.19 just five months ago. With the RSI at 38.8, the market is edging toward oversold conditions—but does that mean a bounce is imminent, or is further downside in store? Recent sell volume spikes and bearish VSA patterns suggest institutional distribution, while key support at $669.24 is under pressure. If buyers fail to hold this level, the next move could be decisive. Meanwhile, resistance looms at $693.67, creating a tight battlefield between bulls and bears. With momentum indicators flashing caution and a looming test of critical levels, traders must ask: Is REGN poised for a short-term rally, or are we witnessing the start of an extended breakdown? Stay sharp—this might be the last chance to act before the next major move. NASDAQ-REGN Roadmap: A Pattern-Driven Journey The price action on Regeneron Pharmaceuticals (NASDAQ: REGN) has been painting a vivid picture of institutional maneuvering. By analyzing the sequential Volume Spread Analysis (VSA) and buy/sell volume patterns, we can uncover the footprints of smart money and determine where the next big move might emerge. Let’s break it down step by step. January 22: The Battle Between Bulls and Bears A VSA Buy Pattern Extra 1st appeared, signaling a potential reversal after prolonged selling. The open was at $682.89, but the close dipped to $679.24, showing hesitation. However, a competing Sell Volumes Max pattern on the same day added to the confusion. The key takeaway? The market was indecisive, but the tug-of-war suggested a major breakout was brewing. January 23: Buyers Step Up A surge in buy volumes confirmed the bullish bias. With an open at $692.165 and a close at $694.36, bulls showed their dominance. This validated the previous buy setup and confirmed that institutions were stepping in. January 24: A Bullish Fake-Out? The VSA Manipulation Buy Pattern 3rd hinted at continued strength. The market opened at $680.78 and closed higher at $683.75, pushing past short-term resistance. However, the presence of a Buy Volumes Takeover pattern earlier in the day, which was immediately sold off, hinted at hidden distribution. The market was climbing, but the undercurrent wasn’t as strong as it seemed. January 27-31: Sellers Take Control A clear shift in sentiment emerged as Sell Volumes Max patterns took over. On January 27, the market opened at $685.17 but barely moved, closing at $684.67—a sign of exhaustion. Then, on January 30-31, massive sell volumes hit, confirming distribution. The price tumbled from $684.17 to $676.50, sealing the bearish outlook. Key Takeaway: Where Do We Go From Here? The January 23-24 bullish patterns initially suggested an upside continuation, but the surge in selling pressure from January 27 onward negated that move. The market failed to hold its ground, confirming the strength of the selling signals. With support at $669.24 under fire, the next key zone to watch is $652-655. If bulls don’t reclaim momentum soon, REGN could be setting up for a deeper correction. Stay sharp—the next move is brewing. Technical & Price Action Analysis: Key Levels in Play The market structure on NASDAQ-REGN is shifting, and traders need to keep an eye on these critical levels. If support zones fail to hold, they flip into resistance—trapping late buyers and fueling further downside moves. Likewise, if resistance levels break, they become new bases for continuation plays. Support Levels: 669.24 – The immediate support zone; losing this level could open the floodgates for deeper selling. 592.7 – A major downside target if sellers gain full control. This level previously acted as a demand zone. 547.57 – The last stand for bulls before things get ugly. Below here, expect a momentum flush. Resistance Levels: 693.67 – The first wall bulls need to break for any short-term recovery. A failure here keeps the bears in charge. 707.835 – A psychological pivot; clearing this would suggest a trend shift. 752.54 – Major battle zone. If reached, expect serious profit-taking. 784.1 – Key breakout threshold; breaking and holding above opens the door for a bigger upside run. 810.53 – The big league level. Any rally stalling here signals trend exhaustion. Powerful Support Levels: 945.71 – Long-term structure zone. If the price ever reclaims this level, bulls are fully back in control. 985.9 – The pivot point for a full-blown trend reversal. 1175.16 – The holy grail for long-term investors; reclaiming this would signal a multi-month rally. Powerful Resistance Levels: 575.46 – A historical battleground; failure to hold here sends a strong bearish signal. 549.69 – A make-or-break level for dip buyers. If sellers push below, expect panic exits. The playbook is simple: react, don’t predict. Watch for confirmations, volume shifts, and price reactions at these levels. No clean break? No trade. The market always shows its hand—just follow the footprint. Trading Strategies Using Rays: Precision in Action The "Rays from the Beginning of Movement" concept is built on dynamic Fibonacci-based levels that adapt to market conditions. Unlike traditional support and resistance levels, these rays adjust automatically as price action evolves, providing a leading rather than lagging perspective. The goal is not to predict exact levels but to identify high-probability zones where price interactions signal trend continuation or reversal. These rays interact with VSA dynamics and moving averages, making them powerful confirmation tools. The price will move from ray to ray, establishing first, second, and third trade targets accordingly. Entries should be made only after interaction with the ray and confirmation of direction. Optimistic Scenario: Bullish Ray Interaction Entry near 669.24 (support level + interaction with a rising ray) First target: 693.67 (resistance level aligned with MA50) Second target: 707.83 (breakout level with confirmation from VSA) Third target: 752.54 (major resistance, completion of the wave) 💡 If momentum is strong, price could extend toward 784.1, aligning with long-term trend acceleration. Pessimistic Scenario: Bearish Ray Interaction Entry after breakdown of 669.24 (failure to hold as support flips to resistance) First target: 592.7 (next structural level, confirming bearish intent) Second target: 547.57 (full breakdown level, aligning with MA200 interaction) Third target: 575.46 (major psychological barrier—either reversal or trend continuation) 💡 If the bearish wave extends, price may push toward 549.69, signaling further downside. Potential Trades Based on Ray Interaction Buy from 669.24 → Target 693.67 – Confirmation required via VSA buy volumes. Breakout above 693.67 → Target 707.83 – Only valid if price holds above MA50. Sell below 669.24 → Target 592.7 – Valid only after a strong bearish volume surge. Rejection at 707.83 → Short to 669.24 – Reversal signal from VSA sell zones. Your Turn: Let’s Trade Smart Together! 🚀 If this analysis makes sense to you, hit that Boost and save this idea—because the key to trading is understanding the levels where trades can be executed. Follow how the price moves and compare it to my setup. The market always speaks to those who listen. Got questions? Drop them in the comments! Let’s break things down together. If you need an analysis of another asset, let me know—we can figure out the best way to do it. Some I can share for free, while for private setups, we can discuss the details. My strategy automatically plots all rays and levels, but the indicator is available only in Private. If you want to trade using this system, send me a direct message. These rays work on all assets, and price moves like clockwork along them. If you want me to chart your asset, hit Boost and comment below. The more interest, the higher the chance I’ll cover your instrument next! Follow me here on TradingView—no fluff, no hype, just **clear levels and market logic.**🔥
NASDAQ:REGNShort
by brandlabelden
$REGN LongThis is just my observation, but not an advice. Technical: REGN touched its two strong trendline since 2020 and 2021. REGN reached the 50% correction since 2020. REGN is oversold daily and weekly. A significant divergence is observable on daily chart. Price touched SMA 200. Fundamental: P/E: 16.9x (moderate undervalue) Since last ATH NASDAQ:REGN has come up with wide ranges of successful clinical trial outcomes. Nonetheless, prices dropped due to competitive pressures on Eylea. Last week, after significant clinical trial results of Odronextamab and Poze-Cemdi, the market moved up. However, the price slid after the BoA's PT revision. Analyst sentiments: 17 buy, 7 buy, 1 sell (BoA) The long possibility is high from now on.
NASDAQ:REGNLong
by jack_the_real_trader
REGN is oversold (the most since 1998)🐂 Trade Idea: Long - REGN 🔥 Account Risk: 20.00% 📈 Recommended Product: Stock 🔍 Entry: +/- 738.00 🐿 DCA: No 😫 Stop-Loss: 660.00 🎯 Take-Profit #1: 1,200.00 (50%) 🎯 Trail Rest: Yes 🚨🚨🚨 Important: Don’t forget to always wait for strong confirmation once possible entry zone is reached. Trade ideas don’t work all the time no matter how good they look. Do not get a victim of FOMO, there is always another trade idea waiting. 🚨🚨🚨 If you like what you see don’t forget to leave a comment 💬 or smash that like ❤️ button! — REGN is completely oversold (in fear of RFK) and so is the rest of the Pharma sector as well. Nevertheless, REGN is still printing money with double digit growth every year. The fear over political decisions in the US should be used to buy the Pharma sector. The last time REGN was that oversold was in 1998! For me, it is Novo and Regeneron. Both are long-term trades for several months. Upside potential is huge over the next 6 months. — Disclaimer & Disclosures pursuant to §34b WpHG The trades shown here related to stocks, cryptos, commodities, ETFs and funds are always subject to risks. All texts as well as the notes and information do not constitute investment advice or recommendations. They have been taken from publicly available sources to the best of our knowledge and belief. All information provided (all thoughts, forecasts, comments, hints, advice, stop loss, take profit, etc.) are for educational and private entertainment purposes only. Nevertheless, no liability can be assumed for the correctness in each individual case. Should visitors to this site adopt the content provided as their own or follow any advice given, they act on their own responsibility.
NASDAQ:REGNLong
by LGNDRY-Capital
Going Long on Regeneron (REGN)Regeneron Pharmaceuticals (REGN) is a stock that has seen an appreciation in its stock price since the beginning of the year. This trading idea focuses on the company's financial performance and its potential for future growth. Key Metrics: Gross Profit Ratio: Regeneron's gross profit ratio currently stands at 87.18%. This metric measures the efficiency and effectiveness of the company by dividing its gross profit by its total net sales. Research and Development (R&D) Expenditures: Regeneron invests $1 billion annually in R&D. This indicates the company's commitment to innovation and the development of new products. EBITDA: The company's earnings before interest, taxes, depreciation, and amortization (EBITDA) is currently $1.20 billion. This metric provides insights into the company's operating performance. Debt Ratio: Regeneron's debt ratio, which is the ratio of total debts to total assets, stands at 8.81. This indicates a relatively low level of debt compared to its assets. Trading Strategy: This trading idea focuses on companies with a moderate investment horizon and a somewhat high risk tolerance. The strategy is to buy the asset, REGN. Idea Core Logic: This strategy looks for companies that have a high gross profit ratio, indicating efficient and effective performance. It also focuses on companies that invest significantly in R&D, as this suggests a commitment to innovation and future growth. Additionally, companies with a high EBITDA and a low debt ratio are preferred, as they indicate strong financial performance and a healthy balance sheet. In the case of Regeneron Pharmaceuticals, it meets all these criteria with a gross profit ratio of 87.18%, 1 billion annual R&D expenditures, 1.20 billion EBITDA, and a debt ratio of 8.81. These factors suggest that Regeneron has a strong financial position and potential for future growth, making it an attractive investment opportunity. Technical Outlook Regeneron (REGN) bulls are looking to push the stock past a key resistance level at $759.49 as the next upside milestone if bulls maintain their dominance. Technical analysis indicates that a strong downtrend may be forthcoming with short positions being favored when the Commodity Channel Index (CCI) falls below -100. In today's session, Regeneron continued its 12-day uptrend by gaining 0.29%. The stock climbed to $779.89, showing positive momentum. In terms of returns, Regeneron has outperformed the Nasdaq by 0.88% so far this year. It currently has a market cap of $83.25 billion. There were 382,219 shares traded on the day, slightly below the average daily volume of 392,139 shares. Regeneron recently released its earnings figures, reporting 3.16 billion in revenue and earnings per share of 10.24. Market analysts had forecasted revenues of 3 billion and an EPS of 9.92. For the next earnings report, Regeneron is expected to announce revenues of 3.22 billion and an EPS of 10.8. Technical analysis indicates a possible new, strong downtrend for Regeneron. The Commodity Channel Index (CCI) indicator is below -100, suggesting that the market price is unusually low and below its moving average. A bullish engulfing candlestick pattern has also appeared on Regeneron's price chart.
NASDAQ:REGNLong
by NomolosAI
V can C bullish flag pattern breakout very soon in this Pharma.About:- Regeneron Pharmaceuticals, Inc. is a biotechnology company that discover, invent, develops, manufactures and commercializes medicines for the treatment of serious diseases. The company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, pain, infectious diseases, and rare diseases. Now about technical,,,so Regeneron pharmaceuticals in trading in bullish flag pattern since many months and now time has come for breakout. chances are high for breakout as it has done proper consolidation inside the bullish flag pattern...so i am expecting a breakout very soon,,keep an eye on monthly chart once breakout done, could be proper buy for this pharma ticker, and we can expect a rally towards 900+ levels..stop loss could be best support zone for this stock around 739. Thankyou guy's please don't forget to like and follow me for future updates.
NASDAQ:REGNLong
by TraderRahulPal
RectanglePrice is above the .236 of the trend up. Bound in a horizontal trading channel for the time being. Neutral pattern. Some trade inside the rectangle but it will eventually break to one side or the other. No recommendation. EPS (FWD) 42.93 PE (FWD) 17.09 Div Rate (TTM) - Short Interest 1.52% Market Cap $78.35B Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
NASDAQ:REGN
by lauralea